S.-H. Lee

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Antonio Passaro, Jing Wang, Yan Wang et al. · Annals of Oncology · 2023 · 396 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Seo‐Young Park, M.-H. Lee, Minjung Seong et al. · Annals of Oncology · 2020 · 192 citations · Full text

Medicine, Oncology, Pharmacology +17

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients

Joonho Shim, H.S. Kim, Soo‐Chan Kim et al. · Annals of Oncology · 2020 · 149 citations

Medicine, Immunology, Oncology +17

Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia

Yanshuo Cao, Shukui Qin, Suxia Luo et al. · ESMO Open · 2021 · 55 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study

Seo‐Young Park, Jong‐Mu Sun, Yoon‐La Choi et al. · ESMO Open · 2022 · 48 citations · Full text

Medicine, Oncology, Pharmacotherapy +17